Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
105 hedge funds and large institutions have $2.23B invested in Rubius Therapeutics, Inc in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 28 increasing their positions, 34 reducing their positions, and 13 closing their positions.
289% more capital invested
Capital invested by funds: $572M → $2.23B (+$1.65B)
146% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 13
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
21% more funds holding
Funds holding: 87 → 105 (+18)
18% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 34
18% less call options, than puts
Call options by funds: $12.2M | Put options by funds: $14.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.4M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$17.5M |
| 3 |
AG
Artal Group
Luxembourg
|
+$16.1M |
| 4 |
AFM
Abbot Financial Management
Andover,
Massachusetts
|
+$12.8M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$10.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.21M |
| 2 |
JP Morgan Chase
New York
|
-$4.74M |
| 3 |
Renaissance Technologies
New York
|
-$1.87M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$1.02M |
| 5 |
HHAM
HITE Hedge Asset Management
Braintree,
Massachusetts
|
-$932K |
RUBY Hedge Fund Activity: Q1 2021 in Review
105 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q1 2021, worth a combined $2.23B — up 289% from $572M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new RUBY positions and 13 closed out — a net gain of 19 holders — while 28 added to existing stakes and 34 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $31.4M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $5.21M.
- 105 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q1 2021, up from 87 in Q4 2020.
- Funds reported $2.23B of Rubius Therapeutics, Inc stock for Q1 2021, up 289% quarter-over-quarter.
- 32 funds opened new Rubius Therapeutics, Inc positions in Q1 2021 and 13 closed out, a net change of +19 holders.
- The largest Rubius Therapeutics, Inc buyer in Q1 2021 was Fidelity Investments, an estimated $31.4M added.
- The largest Rubius Therapeutics, Inc seller in Q1 2021 was Jacobs Levy Equity Management, an estimated $5.21M sold.
Based on aggregated 13F filings for Q1 2021.